본문 바로가기
  • Home

A Comparative Study of Clinical Papers about Pharmacopuncture in Korea and China - Focusing on Papers about Musculoskeletal and Nervous Diseases -

  • Journal of Korean Medicine Rehabilitation
  • Abbr : JKMR
  • 2009, 19(3), pp.47-67
  • Publisher : The Korean Academy Of Oriental Rehabilitation Medicine
  • Research Area : Medicine and Pharmacy > Korean Medicine

Han-Gil Lee 1 홍서영 1

1대전대학교

Accredited

ABSTRACT

Objectives : To research the trend of the study related to pharmacopuncture about musculoskeletal and nervous diseases in China and to make a comparison with clinical application on pharmacopuncture about musculoskeletal and nervous diseases in China and Korea. Methods : I reviewed and analyzed four Chinese Journals relating pharmacopucture from 2004 to 2008 and two Korean Journals relating pharmacopuncture from 1999 to 2008. Results : The following results were obtained in this study. 1. The pharmacopuncture was often used for diseases of spines and joints. 2. In the medicine of pharmacopuncture, Salviae Miltiorrhizae Radix, Angelicae Gigantis Radix were mainly used in China, and Bee-venom in Korea. 3. As a method of needling, local acupoint and Ashi-point were mainly ueed in both China and Korea. 4. In combined treatments, acupuncture, electronic acupuncture, Chuna, heating acupuncture were mainly used in China, and acupuncture, herb medicine, physiotherapy in Korea. 5. In the case of control group study, compared with other treatments pharmacopuncture was not verified the superiority of effectiveness in China, but in Korea, the effectiveness of a pharmacopuncture could be compared with that of others and the effectivenss of different pharmacopuncture could be compared. Conclusions : As seen above, in Korea, clinician should carry out clinical application about musculoskeletal and nervous diseases with various herbal injections besides Bee-venom. And I think that it will be starting point to use Salviae Miltiorrhizae Radix and Angelicae Gigantis Radix that were often used in China.

Citation status

* References for papers published after 2022 are currently being built.